SBP-101 is a proprietary polyamine licensed by Sun BioPharma, Inc. from the University of Florida in 2011. SunBioPharma, Inc. intends to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. View our presentation (.pdf) »
SBP-102 is currently in non-clinical feasibility evaluation for the treatment of patients with pancreatitis.
SBP-103 is currently in non-clinical exploratory evaluation.
Upcoming Clinical Trials
A first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer is expected to begin enrollment in Q2 of 2018.
Completed Clinical Trials
The First-Time-in-Human Phase 1 study of SBP-101 in patients with pancreatic ductal adenocarcinoma has reached completion in Australia and the United States. A dose-escalation phase is expected to precede an expansion phase at the Maximum Tolerated Dose.
Click here for more information regarding the First-Time-in-Human Phase 1 study of SBP-101 in Australia.
Click here for more information regarding in the First-Time-in-Human Phase 1 study of SBP-101 in the United States.